Cargando…

Scorpion Venom Active Polypeptide May Be a New External Drug of Diabetic Ulcer

BACKGROUND: The epidermal growth factor (EGF) is recognized medicine of therapy in ulcer. However, its efficacy has been challenged. We compared scorpion venom active polypeptide and EGF of therapeutic effects in diabetic ulcer. METHODS: The scorpion venom active polypeptide is made into gel. Fourte...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Ting, Li, Luocheng, Zhu, Zhanyong, Liu, Siyang, Zhao, Yueqiang, Yu, Mosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682090/
https://www.ncbi.nlm.nih.gov/pubmed/29234410
http://dx.doi.org/10.1155/2017/5161565
_version_ 1783278040334204928
author Wan, Ting
Li, Luocheng
Zhu, Zhanyong
Liu, Siyang
Zhao, Yueqiang
Yu, Mosheng
author_facet Wan, Ting
Li, Luocheng
Zhu, Zhanyong
Liu, Siyang
Zhao, Yueqiang
Yu, Mosheng
author_sort Wan, Ting
collection PubMed
description BACKGROUND: The epidermal growth factor (EGF) is recognized medicine of therapy in ulcer. However, its efficacy has been challenged. We compared scorpion venom active polypeptide and EGF of therapeutic effects in diabetic ulcer. METHODS: The scorpion venom active polypeptide is made into gel. Fourteen diabetic SD rats were randomly divided into scorpion peptide gel group (SPG group) and EGF group. Before treatment, the rat model of diabetic ulcer was created. The levels of IL-1, IL-6, IL-8, and TNF-α in the wound tissue were measured at different time points during the treatment, secretions of wound were collected for bacterial culture, and the wound healing was recorded. RESULTS: Wound healing was faster in SPG group compared to EGF group (3 weeks versus 5 weeks, t-test, p = 0.032). The levels of IL-1, IL-6, IL-8, and TNF-α were not statistically different when the wounds were formed but showed significant differences from the 2nd to the 5th week between two groups. The infection rate was higher in the EGF group (42.86% versus 0, Chi-square test, p = 0.025). CONCLUSIONS: Scorpion venom active polypeptide shortens wound healing with a stronger anti-inflammation and antibacterial effect and may be a new and effective topical drug for the treatment of diabetic ulcers.
format Online
Article
Text
id pubmed-5682090
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-56820902017-12-11 Scorpion Venom Active Polypeptide May Be a New External Drug of Diabetic Ulcer Wan, Ting Li, Luocheng Zhu, Zhanyong Liu, Siyang Zhao, Yueqiang Yu, Mosheng Evid Based Complement Alternat Med Research Article BACKGROUND: The epidermal growth factor (EGF) is recognized medicine of therapy in ulcer. However, its efficacy has been challenged. We compared scorpion venom active polypeptide and EGF of therapeutic effects in diabetic ulcer. METHODS: The scorpion venom active polypeptide is made into gel. Fourteen diabetic SD rats were randomly divided into scorpion peptide gel group (SPG group) and EGF group. Before treatment, the rat model of diabetic ulcer was created. The levels of IL-1, IL-6, IL-8, and TNF-α in the wound tissue were measured at different time points during the treatment, secretions of wound were collected for bacterial culture, and the wound healing was recorded. RESULTS: Wound healing was faster in SPG group compared to EGF group (3 weeks versus 5 weeks, t-test, p = 0.032). The levels of IL-1, IL-6, IL-8, and TNF-α were not statistically different when the wounds were formed but showed significant differences from the 2nd to the 5th week between two groups. The infection rate was higher in the EGF group (42.86% versus 0, Chi-square test, p = 0.025). CONCLUSIONS: Scorpion venom active polypeptide shortens wound healing with a stronger anti-inflammation and antibacterial effect and may be a new and effective topical drug for the treatment of diabetic ulcers. Hindawi 2017 2017-10-29 /pmc/articles/PMC5682090/ /pubmed/29234410 http://dx.doi.org/10.1155/2017/5161565 Text en Copyright © 2017 Ting Wan et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wan, Ting
Li, Luocheng
Zhu, Zhanyong
Liu, Siyang
Zhao, Yueqiang
Yu, Mosheng
Scorpion Venom Active Polypeptide May Be a New External Drug of Diabetic Ulcer
title Scorpion Venom Active Polypeptide May Be a New External Drug of Diabetic Ulcer
title_full Scorpion Venom Active Polypeptide May Be a New External Drug of Diabetic Ulcer
title_fullStr Scorpion Venom Active Polypeptide May Be a New External Drug of Diabetic Ulcer
title_full_unstemmed Scorpion Venom Active Polypeptide May Be a New External Drug of Diabetic Ulcer
title_short Scorpion Venom Active Polypeptide May Be a New External Drug of Diabetic Ulcer
title_sort scorpion venom active polypeptide may be a new external drug of diabetic ulcer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682090/
https://www.ncbi.nlm.nih.gov/pubmed/29234410
http://dx.doi.org/10.1155/2017/5161565
work_keys_str_mv AT wanting scorpionvenomactivepolypeptidemaybeanewexternaldrugofdiabeticulcer
AT liluocheng scorpionvenomactivepolypeptidemaybeanewexternaldrugofdiabeticulcer
AT zhuzhanyong scorpionvenomactivepolypeptidemaybeanewexternaldrugofdiabeticulcer
AT liusiyang scorpionvenomactivepolypeptidemaybeanewexternaldrugofdiabeticulcer
AT zhaoyueqiang scorpionvenomactivepolypeptidemaybeanewexternaldrugofdiabeticulcer
AT yumosheng scorpionvenomactivepolypeptidemaybeanewexternaldrugofdiabeticulcer